Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Brehanna Edwards, PGY-2 Health-System Pharmacy Administration and Leadership Resident at Ascension, shared on LinkedIn:
”Publication Alert
I’m excited to share that our latest work, “Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE,” has just been published in the Journal of Thrombosis and Thrombolysis.
This multicenter study across 29 hospitals examined whether patients with acute VTE who received prior therapeutic parenteral anticoagulation truly require a full lead-in period of apixaban or rivaroxaban.
Our findings suggest that a reduced lead-in strategy is not associated with increased risk of VTE recurrence or major bleeding, offering important real-world evidence to inform clinical decision-making.
Grateful for the collaborative effort behind this project and excited for the ongoing conversation about optimizing anticoagulation strategies in acute VTE care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria